See All Slides - tctmd.com

Slides

Presentation

Same-Day Discharge Compared with Overnight Hospitalization After Uncomplicated PCI

Presenter: E. Abdelaal

January 22, 2013

Presentation Cell Therapy 2013

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

Presenter: Eduardo Marb?n

January 22, 2013

Presentation Cell Therapy 2013

SDF-1 Plasmid for Treatment of Critical Limb Ischemia

Presenter: David Paul Slovut

January 22, 2013

Presentation Cell Therapy 2013

Multimodality Imaging: Enhancing Outcomes with Available Technology

Presenter: Amish Raval

January 22, 2013

Presentation Cell Therapy 2013

STEM-AMI trial: cMRI and other observations at 3 years

Presenter: Giulio Pompilio

January 22, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Presenter: Kenneth M. Borow

January 22, 2013

Presentation Cell Therapy 2013

SDF-1: Final Results of a Phase 1 Trial and Status of STOP-HF Study

Presenter: Marc S. Penn

January 22, 2013

Presentation Cell Therapy 2013

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells

Presenter: Kenneth Borow

January 22, 2013

Presentation Cell Therapy 2013

IMPACT Clinical Trial Program: Findings and Strategic Update

Presenter: Jay H. Traverse

January 22, 2013

Presentation Cell Therapy 2013

CD-34+ Cells for Ischemic Heart Failure

Presenter: Bojan Vrtovec

January 22, 2013

Advertisement

Slides

Same-Day Discharge Compared with Overnight Hospitalization After Uncomplicated PCI

Cardiac-derived Stem Cells Post-MI: CADUCEUS and ALLSTAR

SDF-1 Plasmid for Treatment of Critical Limb Ischemia

Multimodality Imaging: Enhancing Outcomes with Available Technology

STEM-AMI trial: cMRI and other observations at 3 years

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

SDF-1: Final Results of a Phase 1 Trial and Status of STOP-HF Study

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells

IMPACT Clinical Trial Program: Findings and Strategic Update

CD-34+ Cells for Ischemic Heart Failure

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content